Blockade of the vaspin-AP-1 axis inhibits arthritis development

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Osteoarthritis (OA) involves signal transduction mediated by catabolic factors.
• Vaspin, a novel adipokine, is implicated as a pathogenic ligand in OA, but its precise role and therapeutic potential are unclear.

Purpose of the Study:

• To investigate the function of vaspin in articular chondrocytes and OA.
• To explore the therapeutic efficacy of targeting the vaspin pathway in OA models.

Main Methods:

• RNA sequencing and Ingenuity Pathway Analysis (IPA) were used to analyze vaspin's role in chondrocytes.
• Studies were conducted on human OA cartilage, destabilization of the medial meniscus (DMM) mice, and vaspin transgenic (Tg) and knockout (KO) mice.
• In silico and biochemical analyses identified signaling pathways activated by vaspin.
• A vaspin-targeting nanobody was developed and tested for intra-articular injection in DMM mice.

Main Results:

• Vaspin upregulation in chondrocytes triggers OA development-related signaling pathways.
• Vaspin is elevated in OA cartilage and DMM mouse models, inducing catabolic factor expression.
• Vaspin activates p38 and JNK signaling pathways, leading to AP-1-driven catabolic factor production and cartilage breakdown.
• Vaspin Tg mice exhibited severe cartilage degradation, while vaspin KO mice showed reduced OA development.
• Intra-articular injection of a vaspin-targeting nanobody effectively blocked the vaspin-AP-1 axis and treated OA in DMM mice.

Conclusions:

• The vaspin-AP-1 axis is a key mediator of osteoarthritis pathogenesis.
• Blocking the vaspin-AP-1 axis using targeted nanobodies represents a potential therapeutic strategy for osteoarthritis.
• Further research into vaspin-targeting therapies could lead to novel treatments for OA.